BioMerieux
bioMérieux SA is a France-based in vitro diagnostics company developing biological systems for clinical and industrial diagnostic applications. The enterprise structures its operational activities into two primary segments: Clinical Applications and Industrial Applications. Its diagnostic product portfolio includes automated reagent kits, diagnostic instruments, and software systems used in clinical microbiology, immunoassays, and molecular diagnostics. Revenue is generated predominantly through recurring sales of diagnostic test reagents and single-use consumables, complemented by instrument sales and service contracts. Key end markets include hospital clinical laboratories, commercial medical testing facilities, agri-food processors, and pharmaceutical manufacturers worldwide. bioMérieux occupies the world-leading market position in clinical microbiology diagnostics. The company is headquartered in Marcy-l'Étoile, France, and its shares are publicly traded on Euronext Paris under the ticker symbol BIM.
29 of the funds FundTelligence covers report a position in BioMerieux.
- Sector
- Health Care
- Country
- France
- Funds holding it
- 29
Funds holding BioMerieux
- Handelsbanken Europa SMB — Handelsbanken · 0.84 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.49 % (full portfolio disclosed, October 2026)
- Nordea European Sustainable Enhanced — Nordea Funds · 0.29 % (full portfolio disclosed, September 2026)
- Nordea European Enhanced — Nordea Funds · 0.25 % (full portfolio disclosed, September 2026)
- Nordea Europe Enhanced — Nordea Funds · 0.25 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 0.2 % (full portfolio disclosed, October 2026)
- Storebrand Europa — Storebrand · 0.1 % (full portfolio disclosed, October 2026)
- Storebrand Europa Plus — Storebrand · 0.06 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 29 funds holding it.